Journal
ONCOLOGIST
Volume -, Issue -, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/oncolo/oyac145
Keywords
colorectal cancer; frail patient; elderly patients; panitumumab
Categories
Funding
- Osaka Gastrointestinal Cancer Chemotherapy Study Group - Takeda Pharmaceutical Company Limited
Ask authors/readers for more resources
This study presents a survival analysis of panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer. The results showed favorable overall survival in these patients, particularly in those with left-sided tumors.
Background We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis. Methods Patients aged >= 65 years and considered unsuitable for intensive chemotherapy or aged >= 76 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs). Results Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P = .120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P = .043]. Conclusion Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528). This article presents a survival analysis of the phase II OGSG1602 trial on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available